Fertility and Sterility
Volume 91, Issue 5 , Pages 1842-1847 , May 2009

Cetrorelix protocol versus gonadotropin-releasing hormone analog suppression long protocol for superovulation in intracytoplasmic sperm injection patients older than 40

Received 12 December 2007 ,Revised 26 February 2008 ,Accepted 26 February 2008.

References 

  1. Porter RN, Smith W, Craft IL, Abdulwanhid NA, Jacobs HS. Induction of ovulation for in-vitro fertilisation using buserelin and gonadotropins. Lancet. 1984;2:1284–1285
  2. Smitz J, Devroey P, Braeckmans P, Camus M, Van Waesberghe L, Wisanto A, et al. Management of failed cycles in an IVF/GIFT programme with the combination of a GnRH analogue and HMG. Hum Reprod. 1987;4:309–314
  3. Hughes EG, Fedorkow DM, Daya S, Sagle MA, Van de Koppel P, Collins JA. The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials. Fertil Steril. 1992;5:888–896
  4. Harrison R, Kondaveeti U, Barry-Kinsella C, Gordon A, Drudy L, Cottell E, et al. Should gonadotropin-releasing hormone down-regulation therapy be routine in vitro fertilization?. Fertil Steril. 1994;62:568–573
  5. Neveu S, Hedon B, Bringer J, Chinchole JM, Arnal F, Humeau C, et al. Ovarian stimulation by a combination of a gonadotropin-releasing hormone agonist and gonadotropins for in vitro fertilization. Fertil Steril. 1987;47:639–643
  6. Rutherford AJ, Subak-Sharpe RJ, Dawson KJ, Margara RA, Franks S, Winston RM. Improvement of in vitro fertilisation after treatment with buserelin, an agonist of luteinizing hormone releasing hormone. Br Med J. 1988;25:1765–1768
  7. Janssens RM, Lambalk CB, Vermeiden JP, Schats R, Bernards JM, Rekers-Mombarg LT, et al. Dose-finding study of triptorelin acetate for the prevention of a premature LH surge in IVF: a prospective, randomized, double-blind, placebo-controlled study. Hum Reprod. 2000;15:2333–2340
  8. Diedrich K, Diedrich C, Santos E, Zoll C, al-Hasani S, Reissmann T, et al. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation. Hum Reprod. 1994;9:788–791
  9. Olivennes F, Fanchin R, Bouchard P, de Ziegler D, Taieb J, Selva J, et al. The single or dual administration of the gonadotropin-releasing hormone antagonist Cetrorelix in an in vitro fertilization–embryo transfer program. Fertil Steril. 1994;62:468–476
  10. Olivennes F, Fanchin R, Bouchard P, Taieb J, Selva J, Frydman R. Scheduled administration of a gonadotrophin-releasing hormone antagonist (Cetrorelix) on day 8 of in-vitro fertilization cycles: a pilot study. Hum Reprod. 1995;10:1382–1386
  11. Reissmann T, Felberbaum R, Diedrich K, Engel J, Comaru-Schally AM, Schally AV. Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: an overview. Hum Reprod. 1995;10:1974–1981
  12. Felberbaum R, Reissmann T, Kupker W, Al-Hasani S, Bauer O, Schill T, et al. Hormone profiles under ovarian stimulation with human menopausal gonadotropin (hMG) and concomitant administration of the gonadotropin releasing hormone (GnRH)-antagonist Cetrorelix at different dosages. J Assist Reprod Genet. 1996;13:216–222
  13. Albano C, Smitz J, Camus M, Riethmuller-Winzen H, Van Steirteghem A, Devroey P. Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation. Fertil Steril. 1997;67:917–922
  14. Olivennes F, Alvarez S, Bouchard P, Fanchin R, Salat-Baroux J, Frydman R. The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF–embryo transfer: a dose finding study of 3 versus 2 mg. Hum Reprod. 1998;13:2411–2414
  15. Albano C, Smitz J, Tournaye H, Riethmuller-Winzen H, Van Steirteghem A, Devroey P. Luteal phase and clinical outcome after human menopausal gonadotrophin/gonadotrophin releasing hormone antagonist treatment for ovarian stimulation in in-vitro fertilization/intracytoplasmic sperm injection cycles. Hum Reprod. 1999;14:1426–1430
  16. Olivennes F, Belaisch-Allart J, Emperaire JC, Dechaud H, Alvarez S, Moreau L, et al. Prospective, randomized, controlled study of in vitro fertilization–embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Fertil Steril. 2000;73:314–320
  17. Albano C, Felberbaum RE, Smitz J, Riethmuller-Winzen H, Engel J, Diedrich K, et al. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group. Hum Reprod. 2000;15:526–531
  18. Felberbaum RE, Albano C, Ludwig M, Riethmuller-Winzen H, Grigat M, Devroey P, et al. Ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GnRH antagonist cetrorelix according to the multiple dose protocol: a prospective uncontrolled phase III study. Hum Reprod. 2000;15:1015–1020
  19. Ludwig M, Katalinic A, Banz C, Schroder AK, Loning M, Weiss JM, et al. Tailoring the GnRH antagonist cetrorelix acetate to individual patients' needs in ovarian stimulation for IVF: results of a prospective, randomized study. Hum Reprod. 2002;17:2842–2845
  20. Loutradis D, Stefanidis K, Drakakis P, Milingos S, Antsaklis A, Michalas S. A modified gonadotropin-releasing hormone (GnRH) antagonist protocol failed to increase clinical pregnancy rates in comparison with the long GnRH protocol. Fertil Steril. 2004;82:1446–1448
  21. Wilcox J, Potter D, Moore M, Ferrande L, Kelly E Cap IV Investigator Group. Prospective, randomized trial comparing cetrorelix acetate and ganirelix acetate in a programmed, flexible protocol for premature luteinizing hormone surge prevention in assisted reproductive technologies. Fertil Steril. 2005;84:108–117
  22. Craft I, Gorgy A, Hill J, Menon D, Podsiadly B. Will GnRH antagonists provide new hope for patients considered “difficult responders” to GnRH agonist protocols?. Hum Reprod. 1999;14:2959–2962
  23. Akman MA, Erden HF, Tosun SB, Bayazit N, Aksoy E, Bahceci M. Addition of GnRH antagonist in cycles of poor responders undergoing IVF. Hum Reprod. 2000;15:2145–2147
  24. Akman MA, Erden HF, Tosun SB, Bayazit N, Aksoy E, Bahceci M. Comparison of agonistic flare-up-protocol and antagonistic multiple dose protocol in ovarian stimulation of poor responders: results of a prospective randomized trial. Hum Reprod. 2001;16:868–870
  25. Cheung LP, Lam PM, Lok IH, Chiu TT, Yeung SY, Tjer CC, et al. GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial. Hum Reprod. 2005;20:616–621
  26. Mohamed KA, Davies WA, Allsopp J, Lashen H. Agonist “flare-up” versus antagonist in the management of poor responders undergoing in vitro fertilization treatment. Fertil Steril. 2005;83:331–335
  27. Shapiro DB, Mitchell-Leef D, Carter M, Nagy ZP. Ganirelix acetate use in normal- and poor-prognosis patients and the impact of estradiol patterns. Fertil Steril. 2005;83:666–670
  28. Schmidt DW, Bremner T, Orris JJ, Maier DB, Benadiva CA, Nulsen JC. A randomized prospective study of microdose leuprolide versus ganirelix in in vitro fertilization cycles for poor responders. Fertil Steril. 2005;83:1568–1571
  29. Chung K, Krey L, Katz J, Noyes N. Evaluating the role of exogenous luteinizing hormone in poor responders undergoing in vitro fertilization with gonadotropin-releasing hormone antagonists. Fertil Steril. 2005;84:313–318
  30. Malmusi S, La Marca A, Giulini S, Xella S, Tagliasacchi D, Marsella T, et al. Comparison of a gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare-up regimen in poor responders undergoing ovarian stimulation. Fertil Steril. 2005;84:402–406
  31. Sbracia M, Farina A, Poverini R, Morgia F, Schimberni M, Aragona C. Short versus long gonadotropin-releasing hormone analogue suppression protocols for superovulation in patients ≥40 years old undergoing intracytoplasmic sperm injection. Fertil Steril. 2005;84:644–648
  32. Palermo G, Joris H, Devroey P, Van Sterteghen AL. Pregnancies after intracytoplasmic injection of single spermatozoon into an oocyte. Lancet. 1992;340(17):8
  33. Veeck LL. An atlas of human gametes and conceptus. London, UK: Parthenon Publishing; 1999;
  34. Al-Inany HG, Abou-Setta AM, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev. 2006;3:CD001750
  35. Griesinger G, Diedrich K, Tarlatzis BC, Kolibianakis EM. GnRH-antagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: a meta-analysis. Reprod Biomed Online. 2006;13:628–638
  36. Acevedo B, Sanchez M, Gomez JL, Cuadros J, Ricciarelli E, Hernandez ER. Luteinizing hormone supplementation increases pregnancy rates in gonadotropin-releasing hormone antagonist donor cycles. Fertil Steril. 2004;82:343–347
  37. Griesinger G, Schultze-Mosgau A, Dafopoulos K, Schroeder A, Schroer A, von Otte S, et al. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol. Hum Reprod. 2005;20:1200–1206
  38. Cedrin-Durnerin I, Grange-Dujardin D, Laffy A, Parneix I, Massin N, Galey Theron L, et al. Recombinant human LH supplementation during GnRH antagonist administration in IVF/ICSI cycles: a prospective randomized study. Hum Reprod. 2004;19:1979–1984
  39. Klein NA, Harper AJ, Houmard BS, Sluss PM, Soules MR. Is the short follicular phase in older women secondary to advanced or accelerated dominant follicle development?. J Clin Endocrinol Metab. 2002;87:5746–5750
  40. van Zonneveld P, Scheffer GJ, Broekmans FJ, Blankenstein MA, de Jong FH, Looman CW, et al. Do cycle disturbances explain the age-related decline of female fertility? Cycle characteristics of women aged over 40 years compared with a reference population of young women. Hum Reprod. 2003;18:495–501
  41. Klein NA, Battaglia DE, Fujimoto VY, Davis GS, Bremner WJ, Soules MR. Reproductive aging: accelerated ovarian follicular development associated with a monotropic follicle-stimulating hormone rise in normal older women. J Clin Endocrinol Metab. 1996;81:1038–1045
  42. Klein NA, Illingworth PJ, Groome NP, McNeilly AS, Battaglia DE, Soules MR. Decreased inhibin B secretion is associated with the monotropic FSH rise in older, ovulatory women: a study of serum and follicular fluid levels of dimeric inhibin A and B in spontaneous menstrual cycles. J Clin Endocrinol Metab. 1996;81:2742–2745
  43. Mahutte NG, Arici A. Role of gonadotropin-releasing hormone antagonists in poor responders. Fertil Steril. 2007;87:241–249

 M.S. has nothing to disclose. J.C. has nothing to disclose. A.G. has nothing to disclose. P.G. has nothing to disclose. C.P. has nothing to disclose. F.M. has nothing to disclose. M.M. has nothing to disclose. M.S. has nothing to disclose.

PII: S0015-0282(08)00525-6

doi: 10.1016/j.fertnstert.2008.02.165

Fertility and Sterility
Volume 91, Issue 5 , Pages 1842-1847 , May 2009

Article Tools